News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: Luye Acquires Hanmi Pharmaceutical, Co., Ltd's Oncology Drug For $20 Million



8/25/2014 9:07:02 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Luye Pharma in-licensed China rights to a novel oncology drug candidate from Korea's Hanmi Pharma in a $20 million deal; Bao Hao, a Shanghai company, made an equity investment in US-based 20/20 GeneSystems to underwrite a China trial of 20/20's lung cancer diagnostic; Sinopharm signed a MOU to in-license China rights for a cancer immunotherapy from Provectus Biopharma of the US; Suzhou Amerigen Pharma gained CFDA approval to sell generic mecobalamin tablets, its first marketed product; a Wuxi PharmaTech subsidiary passed FDA inspection for manufacture of a commercialized drug API; and Cook Medical of the US began enrolling patients in a China trial of its drug eluting peripheral stent.

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES